NCT02713269 2026-04-17
Thermal Ablation and Spine Stereotactic Radiosurgery in Treating Patients With Spine Metastases at Risk for Compressing the Spinal Cord
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
Clinical Trials
225 trialsNCT05197322 2026-04-17
NEOPRISM-CRC
University College, London
Phase 2 Recruiting
NCT05513742 2026-04-17
COMPANION-003
Compass Therapeutics
Phase 2 Completed
NCT05775159 2026-04-17
Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer
AstraZeneca
Phase 2 Recruiting
NCT06050252 2026-04-17
Testing the Combination of the Anticancer Drug Durvalumab With Chemotherapy (Gemcitabine and Cisplatin) at Improving Outcomes for High-Risk Resectable Liver Cancer Before Surgery
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT06233981 2026-04-17
Phase II Study of Moderate-dose Hypofractionated RT Combined With Tislelizumab for HCC With Diffuse Tumor Thrombosis
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Completed
NCT06760702 2026-04-17
TEJAS-2
Aurigene Discovery Technologies Limited
Phase 2 Terminated
NCT06855225 2026-04-17
A Phase II Study of Single Tremelimumab With Regular Interval Durvalumab Plus Gemcitabine and Cisplatin in Locally Advanced Unresectable/Metastatic Combined Hepatocellular-cholangiocarcinoma
Hoosier Cancer Research Network
Phase 2 Not yet recruiting
NCT07405476 2026-04-17
Zanidatamab Before Surgery for the Treatment of HER2 Positive Colon and Rectal Cancer in Patients Planned for Curative Intent Treatment
Emory University
Phase 2 Recruiting
NCT07406633 2026-04-17
KQB198 in Combination With Imatinib in Participants With Advanced/Metastatic GIST in 1st Line Setting
Kumquat Biosciences Inc.
Phase 2 Recruiting
NCT07523763 2026-04-17
NIVO1002024
Blokhin's Russian Cancer Research Center
Phase 2 Active not recruiting
NCT07535632 2026-04-17
BEST
Shanghai Zhongshan Hospital
Phase 2 Not yet recruiting
NCT07537348 2026-04-17
LUCENT-GC-03
Qilu Hospital of Shandong University
Phase 2 Recruiting
NCT07537361 2026-04-17
LUCENT-GC-02
Qilu Hospital of Shandong University
Phase 2 Recruiting
NCT07537777 2026-04-17
Benmelstobart Plus Anlotinib Combined With SBRT for Patients With Hepatocellular Carcinoma Failing First-Line Targeted Therapy
Nanfang Hospital, Southern Medical University
Phase 2 Not yet recruiting
NCT07537972 2026-04-17
Denosumab Strategy for Liver Cancer With Bone Metastases
Tongji Hospital
Phase 2 Not yet recruiting
NCT03259867 2026-04-16
TATE-PD1
Teclison Ltd.
Phase 2 Recruiting
NCT04355156 2026-04-16
AXMUS-C
Imperial College London
Phase 2 Completed
NCT04661150 2026-04-16
A Study of Atezolizumab and Trastuzumab in Combination With Capecitabine and Oxaliplatin in Patients With HER2 Positive Locally Advanced Resectable Gastric Cancer of Adenocarcinoma of Gastroesophageal Junction
Hoffmann-La Roche
Phase 2 Active not recruiting
NCT04701476 2026-04-16
TATE and Pembrolizumab (MK3475) in mCRC and NSCLC
Teclison Ltd.
Phase 2 Recruiting
NCT04940286 2026-04-16
Gemcitabine, Nab-paclitaxel, Durvalumab, and Oleclumab Before Surgery for the Treatment of in Resectable/Borderline Resectable Primary Pancreatic Cancer
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT05789485 2026-04-16
A Study on the Effects of Exercise on Side Effects From Treatment for Gastrointestinal Cancers
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT05967182 2026-04-16
A Single-Arm Study of Pembrolizumab With Gemcitabine and Cisplatin as Perioperative Therapy for Potentially Resectable Intrahepatic Cholangiocarcinoma
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT06453486 2026-04-16
ABLATE
University Health Network, Toronto
Phase 2 Recruiting
NCT06569368 2026-04-16
Trial Utilizing Metronidazole to Optimize the Microbiome of Rectal Adenocarcinoma Undergoing Neoadjuvant Therapy
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT06617858 2026-04-16
Trial of AMB-05X for Patients With ctDNA(+) Colorectal Cancer After Curative-intent Treatment
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT07223424 2026-04-16
PSI-Immune
University of Pittsburgh
Phase 2 Recruiting
NCT07283705 2026-04-16
A Phase II Study Evaluating BMS-986504 in MTAP-deleted Pancreatic Cancer
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT07294664 2026-04-16
PD1/TGFβ In Combination With SHR2554 or Apatinib And Chemotherapy For First - Line Treatment Of Gastric Cancer
The First Affiliated Hospital of Zhengzhou University
Phase 2 Recruiting
NCT01512589 2026-04-15
Proton Beam Therapy (PBT) Versus Intensity-Modulated Radiation Therapy (IMRT) Trial
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT02143219 2026-04-15
PAMELA70
Institut Cancerologie de l'Ouest
Phase 2 Completed
NCT03161522 2026-04-15
Chemotherapy With or Without Radiation or Surgery in Treating Participants With Oligometastatic Esophageal or Gastric Cancer
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT03682289 2026-04-15
Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors
University of California, San Francisco
Phase 2 Recruiting
NCT03776487 2026-04-15
Nivolumab, Ipilimumab and Chemoradiation in Treating Patients With Resectable Gastric Cancer
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT04481204 2026-04-15
New and Emerging Therapies for the Treatment of Resectable, Borderline Resectable, or Locally Advanced Pancreatic Cancer, PIONEER-Panc Study
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT04486378 2026-04-15
A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage III Colorectal Cancer
BioNTech SE
Phase 2 Recruiting
NCT04858334 2026-04-15
APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT05065801 2026-04-15
GABRINOX2
Institut du Cancer de Montpellier - Val d'Aurelle
Phase 2 Recruiting
NCT06638931 2026-04-15
ANTARES
Instituto do Cancer do Estado de São Paulo
Phase 2 Recruiting
NCT06659705 2026-04-15
INDIGO-FAPI
Institut Curie
Phase 2 Recruiting
NCT06820463 2026-04-15
AndroMETa-CRC
AbbVie
Phase 2 Recruiting
NCT07126158 2026-04-15
Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic Adenocarcinoma
Washington University School of Medicine
Phase 2 Recruiting
NCT07403136 2026-04-15
Vebrekotuzumab ± Anti-PD-1 in Pretreated Advanced ESCC
Fudan University
Phase 2 Suspended
NCT07438106 2026-04-15
A Phase II Study of HRS-4642 Combined With AG (Nab-paclitaxel and Gemcitabine) as Conversion Therapy for Locally Advanced Pancreatic Cancer
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Recruiting
NCT07519486 2026-04-15
INS-ESCC-CT
Sichuan University
Phase 2 Recruiting
NCT07530094 2026-04-15
STELLAR01
Jiangsu Cancer Institute & Hospital
Phase 2 Recruiting
NCT07530445 2026-04-15
Phase II Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Albumin-Bound Paclitaxel and Lenvatinib as Second-Line Therapy for Unresectable or Metastatic Biliary Tract Cancer
Sun Yat-sen University
Phase 2 Recruiting
NCT07530549 2026-04-15
A Phase II Single-arm Clinical Study in the Treatment of Locally Advanced Esophageal Cancer After Failed Neoadjuvant Chemoimmunotherapy
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Not yet recruiting
NCT03155620 2026-04-14
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT04736485 2026-04-14
GASPAR
Centre Francois Baclesse
Phase 2 Active not recruiting